Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome

NCT05064930

Irritable Bowel Syndrome

COMPLETED NA

Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome

NCT02213172

Irritable Bowel Syndrome

COMPLETED PHASE2

Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)

NCT04053790

Irritable Bowel Syndrome With Diarrhea

COMPLETED PHASE4

Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome

NCT01886781

Irritable Bowel Syndrome

COMPLETED PHASE4

Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome

NCT02545413

Irritable Bowel Syndrome

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Given the promising clinical results of previous trials of probiotics for IBS symptoms, the objective of this clinical trial is to evaluate the safety and effectiveness of a proprietary probiotic product, Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2® on symptoms of IBS in otherwise healthy adults.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic capsules

L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.

Group Type ACTIVE_COMPARATOR

L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®

Intervention Type DIETARY_SUPPLEMENT

Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.

Placebo capsules

The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®

Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.

Intervention Type DIETARY_SUPPLEMENT

Placebo

The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bio-K+

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 years or older
2. Subject meets Rome III criteria for IBS (regardless of IBS subtype) as follows:

* Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with 2 or more of the following:

* Improvement with defecation
* Onset associated with a change in frequency of stool
* Onset associated with a change in form (appearance) of stool
* Symptom onset must be at least 6 months prior to diagnosis
3. Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
4. Able to understand the nature and purpose of the study including potential risks and side effects
5. Willing to consent to study participation and to comply with study requirements

* Abdominal pain or discomfort at least 2 days during run-in period associated with 2 or more of the following:

* Improvement with defecation
* Onset associated with a change in frequency of stool
* Onset associated with a change in form (appearance) of stool
* Completion of all study-related questionnaires

Exclusion Criteria

1. Diagnosed gastrointestinal disease, e.g. Crohn's disease, ulcer, cancer
2. Prior abdominal surgery that, in the investigator's opinion, may confound study outcomes
3. Any systemic disease that may confound IBS symptoms or compromise subject safety
4. Life expectancy \< 6 months
5. Pregnant female or breastfeeding
6. Lactose intolerance
7. Immunodeficient subjects
8. Uncontrolled psychiatric disorder
9. Current treatment with nasogastric tube, ostomy, or parenteral nutrition
10. Eating disorder
11. Recent (\< 2 weeks) antibiotic administration
12. History of alcohol, drug, or medication abuse
13. Daily consumption of probiotics, fermented milk, and/or yogurt
14. Known allergies to any substance in the study product
15. Participation in another study with any investigational product within 3 months of screening

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes